Management of chronic myeloid leukemia in chronic phase with autologous stem cell transplantation and alpha-2 interferon: Cytogenetic and clinical results

Giuliana Alimena, Giovanna Meloni, M. Rosaria De Cuia, M. Beatrice Rondinelli, Francesco Lo Coco, Enrico Montefusco, Marco Mancini, Rita Pinto, Mauro Nanni, Michele Cedrone, Paolo De Fabritiis, Franco Mandelli

Research output: Contribution to journalArticle

Abstract

Forty-eight patients with chronic myeloid leukemia (CML) in chronic phase (CP) were treated by autologous stem cells transplantation (ASCT) and α Interferon (IFN) with three approaches: 1) ASCT at diagnosis followed by IFN, 2) ASCT post IFN with cells collected after an interval from IFN discontinuance, followed by IFN, 3) ASCT in patients selected by cytoconversion obtained with IFN, performed soon after IFN discontinuance. Following ASCT, a major karyotype response (more than 65% Ph1 negative cells, MKR) was observed at least once in 40% 53% and 83% of patients from the three groups, respectively. At last follow-ups (median 39, 40 and 21 months, respectively) 19% 13% and 67% of patients still present a MKR with 2 patients from group 1 and 4 patients from group 3 being 100% Ph1 negative. Projected survival from diagnosis is 77% at 52 months for patients from group 1 and 47% at 75 months for patients from group 2. Present data indicate that 1) IFN can stabilize results obtained with ASCT, 2) ASCT can potentiate responses to IFN, 3) combined ASCT and IFN can improve survival. Longer follow-up of patients and randomized studies are required to define the real impact on disease outcome by these treatment approaches.

Original languageEnglish
Pages (from-to)281-291
Number of pages11
JournalLeukemia and Lymphoma
Volume11
Issue numbers1
DOIs
Publication statusPublished - 1993

Fingerprint

Leukemia, Myeloid, Chronic Phase
Stem Cell Transplantation
Interferon-alpha
Cytogenetics
Interferons
Survival
Karyotype

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Management of chronic myeloid leukemia in chronic phase with autologous stem cell transplantation and alpha-2 interferon : Cytogenetic and clinical results. / Alimena, Giuliana; Meloni, Giovanna; De Cuia, M. Rosaria; Rondinelli, M. Beatrice; Coco, Francesco Lo; Montefusco, Enrico; Mancini, Marco; Pinto, Rita; Nanni, Mauro; Cedrone, Michele; Fabritiis, Paolo De; Mandelli, Franco.

In: Leukemia and Lymphoma, Vol. 11, No. s1, 1993, p. 281-291.

Research output: Contribution to journalArticle

Alimena, G, Meloni, G, De Cuia, MR, Rondinelli, MB, Coco, FL, Montefusco, E, Mancini, M, Pinto, R, Nanni, M, Cedrone, M, Fabritiis, PD & Mandelli, F 1993, 'Management of chronic myeloid leukemia in chronic phase with autologous stem cell transplantation and alpha-2 interferon: Cytogenetic and clinical results', Leukemia and Lymphoma, vol. 11, no. s1, pp. 281-291. https://doi.org/10.3109/10428199309047900
Alimena, Giuliana ; Meloni, Giovanna ; De Cuia, M. Rosaria ; Rondinelli, M. Beatrice ; Coco, Francesco Lo ; Montefusco, Enrico ; Mancini, Marco ; Pinto, Rita ; Nanni, Mauro ; Cedrone, Michele ; Fabritiis, Paolo De ; Mandelli, Franco. / Management of chronic myeloid leukemia in chronic phase with autologous stem cell transplantation and alpha-2 interferon : Cytogenetic and clinical results. In: Leukemia and Lymphoma. 1993 ; Vol. 11, No. s1. pp. 281-291.
@article{1d9ee97d97cb412786b1a438e0e6222b,
title = "Management of chronic myeloid leukemia in chronic phase with autologous stem cell transplantation and alpha-2 interferon: Cytogenetic and clinical results",
abstract = "Forty-eight patients with chronic myeloid leukemia (CML) in chronic phase (CP) were treated by autologous stem cells transplantation (ASCT) and α Interferon (IFN) with three approaches: 1) ASCT at diagnosis followed by IFN, 2) ASCT post IFN with cells collected after an interval from IFN discontinuance, followed by IFN, 3) ASCT in patients selected by cytoconversion obtained with IFN, performed soon after IFN discontinuance. Following ASCT, a major karyotype response (more than 65{\%} Ph1 negative cells, MKR) was observed at least once in 40{\%} 53{\%} and 83{\%} of patients from the three groups, respectively. At last follow-ups (median 39, 40 and 21 months, respectively) 19{\%} 13{\%} and 67{\%} of patients still present a MKR with 2 patients from group 1 and 4 patients from group 3 being 100{\%} Ph1 negative. Projected survival from diagnosis is 77{\%} at 52 months for patients from group 1 and 47{\%} at 75 months for patients from group 2. Present data indicate that 1) IFN can stabilize results obtained with ASCT, 2) ASCT can potentiate responses to IFN, 3) combined ASCT and IFN can improve survival. Longer follow-up of patients and randomized studies are required to define the real impact on disease outcome by these treatment approaches.",
author = "Giuliana Alimena and Giovanna Meloni and {De Cuia}, {M. Rosaria} and Rondinelli, {M. Beatrice} and Coco, {Francesco Lo} and Enrico Montefusco and Marco Mancini and Rita Pinto and Mauro Nanni and Michele Cedrone and Fabritiis, {Paolo De} and Franco Mandelli",
year = "1993",
doi = "10.3109/10428199309047900",
language = "English",
volume = "11",
pages = "281--291",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "s1",

}

TY - JOUR

T1 - Management of chronic myeloid leukemia in chronic phase with autologous stem cell transplantation and alpha-2 interferon

T2 - Cytogenetic and clinical results

AU - Alimena, Giuliana

AU - Meloni, Giovanna

AU - De Cuia, M. Rosaria

AU - Rondinelli, M. Beatrice

AU - Coco, Francesco Lo

AU - Montefusco, Enrico

AU - Mancini, Marco

AU - Pinto, Rita

AU - Nanni, Mauro

AU - Cedrone, Michele

AU - Fabritiis, Paolo De

AU - Mandelli, Franco

PY - 1993

Y1 - 1993

N2 - Forty-eight patients with chronic myeloid leukemia (CML) in chronic phase (CP) were treated by autologous stem cells transplantation (ASCT) and α Interferon (IFN) with three approaches: 1) ASCT at diagnosis followed by IFN, 2) ASCT post IFN with cells collected after an interval from IFN discontinuance, followed by IFN, 3) ASCT in patients selected by cytoconversion obtained with IFN, performed soon after IFN discontinuance. Following ASCT, a major karyotype response (more than 65% Ph1 negative cells, MKR) was observed at least once in 40% 53% and 83% of patients from the three groups, respectively. At last follow-ups (median 39, 40 and 21 months, respectively) 19% 13% and 67% of patients still present a MKR with 2 patients from group 1 and 4 patients from group 3 being 100% Ph1 negative. Projected survival from diagnosis is 77% at 52 months for patients from group 1 and 47% at 75 months for patients from group 2. Present data indicate that 1) IFN can stabilize results obtained with ASCT, 2) ASCT can potentiate responses to IFN, 3) combined ASCT and IFN can improve survival. Longer follow-up of patients and randomized studies are required to define the real impact on disease outcome by these treatment approaches.

AB - Forty-eight patients with chronic myeloid leukemia (CML) in chronic phase (CP) were treated by autologous stem cells transplantation (ASCT) and α Interferon (IFN) with three approaches: 1) ASCT at diagnosis followed by IFN, 2) ASCT post IFN with cells collected after an interval from IFN discontinuance, followed by IFN, 3) ASCT in patients selected by cytoconversion obtained with IFN, performed soon after IFN discontinuance. Following ASCT, a major karyotype response (more than 65% Ph1 negative cells, MKR) was observed at least once in 40% 53% and 83% of patients from the three groups, respectively. At last follow-ups (median 39, 40 and 21 months, respectively) 19% 13% and 67% of patients still present a MKR with 2 patients from group 1 and 4 patients from group 3 being 100% Ph1 negative. Projected survival from diagnosis is 77% at 52 months for patients from group 1 and 47% at 75 months for patients from group 2. Present data indicate that 1) IFN can stabilize results obtained with ASCT, 2) ASCT can potentiate responses to IFN, 3) combined ASCT and IFN can improve survival. Longer follow-up of patients and randomized studies are required to define the real impact on disease outcome by these treatment approaches.

UR - http://www.scopus.com/inward/record.url?scp=0027164574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027164574&partnerID=8YFLogxK

U2 - 10.3109/10428199309047900

DO - 10.3109/10428199309047900

M3 - Article

C2 - 7902746

AN - SCOPUS:0027164574

VL - 11

SP - 281

EP - 291

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - s1

ER -